新药贝伐单抗的临床应用进展.pdfVIP

新药贝伐单抗的临床应用进展 陈万灵综述， 欧阳学农审校 （南京军区福州总医院，福建福州 350025 ） 摘 要：血管内皮生长因子(VEGF)在肿瘤血管生成过程中起着关键作用，并已成为抗 肿瘤治疗的重要靶点。 贝伐单抗为重组人源化抗VEGF 的单克隆抗体，其治疗肿瘤具 有良好的效果。 目前， 已批准贝伐单抗用于转移性结直肠癌、转移性乳腺癌、晚期 FDA 非小细胞肺癌、转移性肾细胞癌的一线治疗。 除此之外，贝伐单抗在肝癌、 胃癌、食管癌 等其他恶性肿瘤的应用也取得令人鼓舞的结果。 现就贝伐单抗在多种恶性肿瘤中的临 床应用作一综述。 关键词：贝伐单抗；血管内皮生长因子；靶向治疗；肿瘤 中图分类号： 文献标识码： 文章编号： （ ） R730.53 A 1004-0242 2010 08-0534-06 Clin ica l Progre s s in Ne w Dru g Be va cizu m a b C HEN Wa n -ling , O UYANG Xue -no ng （Fuzho u G e ne ra l Ho sp ita l, Na njing Milita ry C o m m a nd , Fuzho u 350025, C hina ） Abstract: Vascular endothelial growth factor (VEGF) plays a critical role in tumor an- giogenesis and has become an important target for anticancer treatment. Bevacizu- mab, a recombinant humanized anti-VEGF monoclonal antibody, has proven benefi- cial to cancer therapy. Currently, Bevacizumab was approved by the Food and Drug Administration (FDA) for first-line treatment in metastatic colorectal cancer, metastat- ic breast cancer, advanced non-small cell lung cancer and metastatic renal cell carci- noma. In addition, there are some evidences for its challenging efficacy in treatment of other solid tumors, such as hepatocellular carcinoma, gastric cancer, esophageal cancer and so on. The current clinical application of bevacizumab in variety of malig- nancies are reviewed. Key words: bevacizumab; vascular endothelial growth factor; targeted therapy; neoplasms 目前认为血管的生成在肿 抑制血管生成治疗成为抗肿瘤治 单抗在肝癌、 胃癌、食管癌等其他 瘤的发生发展过程中起着关键 疗的一种新策略。 贝伐单抗 恶性肿瘤的应用也取得令人鼓舞